

Memo no.: 2024-026
Date: 15-Jul-2024
Memo to: Clients
Re: Service Discontinuation - Factor XIII Assay (Urea Clot Solubility), Plasma

We have been informed by St. Michael's Hospital, that effective July 22, 2024, the [Factor XIII Assay \(Urea Clot Solubility\), Plasma](#) test will be discontinued. ICL will not accept specimens for the assay effective **July 17, 2024**. Alternatively, those samples with a FXIII request, will have the [Factor XIII Antigen Quantitation, Plasma](#) test performed.

The change is being made as the FXIII Antigen method is more specific and sensitive, and is a quantitative assay, whereas the FXIII Urea Clot Solubility method is considered to primarily be a qualitative assay.

The FXIII Antigen Quantitation test is recommended by St. Michael's Hospital as the assay has been available for approximately 10 years and it has performed well.

If you have further questions, please contact Client Care at 416-422-3000 ext. 300 or info@iclabs.ca

Dr. Shashank Tilak, Ph.D., DCC
Laboratory Director
416-422-3000 ext. 221
shashtilak@iclabs.ca